Leuprorelin - Tolmar

Drug Profile

Leuprorelin - Tolmar

Alternative Names: Eligard; LA 2575; Leuprogel®; SOT-375; SOU 375

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QLT USA
  • Developer Tolmar
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Precocious puberty
  • Discontinued Endometriosis

Most Recent Events

  • 15 May 2017 Pooled pharmacokinetics data from four pivotal studies in Prostate cancer presented at the 112th Annual American Urological Association Meeting in Boston (AUA-2017)
  • 15 Mar 2016 Biomarkers information updated
  • 03 Sep 2015 Hospira has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top